The Limited Times

Now you can see non-English news...

US to resume use of Johnson & Johnson vaccine after 11-day hiatus

2021-04-24T11:45:01.560Z


The nearly two-week hiatus followed isolated reports of blood clots that have turned out to be rare, but serious. The CDC decided to resume the single-dose vaccine after "a comprehensive safety review" and on the recommendation of an expert panel that voted 10-4 with no abstentions.


Johnson & Johnson's vaccine will be resumed in the United States after an 11-day hiatus, the Centers for Disease Control and Prevention (CDC) decided on Friday, after hearing the recommendation of a panel of experts who voted 10-4 with no abstentions to end the hiatus.

The decision was made after "a comprehensive safety review" following isolated reports of

 blood clots in people who received the single-dose vaccine

, the CDC said in a joint statement.

Y

the Food and Drug Administration (FDA).

A few hours earlier, the CDC advisory panel suggested ending the hiatus, but asked to add a warning to Johnson & Johnson vaccines about the risk of clots

which have been very rare, but serious.

"Today's presentations and discussions have convinced me that lifting the J&J vaccine pause is in the best interests of the public health of the United States," said one of the CDC advisory panel members, Dr. Henry. Bernstein.


The United States exceeds 32 million infections of COVID-19 since the start of the pandemic

April 23, 202100: 34

The FDA will be responsible for including the warning on the vaccine label to inform about this possible side effect,

extremely rare.

[Plan your vaccination: this tool helps to know who is eligible and where to schedule an appointment]

"We know it's not good to extend the hiatus any longer than necessary

," Dr. Peter Marks, the FDA's chief vaccine regulator, said Thursday.

A prolonged pause could contribute to increasing doubts about vaccines at a time when the rate of vaccination begins to slow after exceeding 200 million injected doses.

The government's top infectious disease expert, Anthony Fauci, said in several interviews that he expects a decision by Friday.

"I would be very surprised if we didn't have some kind of resumption [of the J&J vaccination] by Friday," Fauci said, "I really don't think they want to extend [the hiatus] any longer."

Fauci, who is chief medical adviser to the president, Joe Biden, further said that

possible restrictions could be based on the age or gender of those

eligible to receive this vaccine.

Federal health agencies recommended on April 13 to stop this vaccine because there were six cases of clots in women between 18 and 48 years old, between 6 and 13 days after being immunized.

One of them died and another was in critical condition.

The clots occurred in the veins that drain blood from the brain and were associated with a low level of platelets.

[Follow our coverage on the coronavirus pandemic]

European medical authorities made a decision similar to what the United States could take, resuming vaccination but adding a warning.

In his opinion, the benefits of the vaccine against a disease that has caused millions of deaths worldwide are greater than the risks found. 

Pfizer and Moderna vaccines effective against two major variants

The Pfizer and Moderna vaccines are effective against two variants, two independent studies have shown.

One of these is the one that was first discovered in the

UK,

B.1.1.7, and is currently the most common in the country.

Both studies, which have not yet been peer-reviewed, also show that both vaccines

prevent serious and fatal diseases

in the case of variant B.1.526, identified in

New York

in November.

The antibodies that these vaccines generate are only

slightly less potent

in people infected with some of these variants.

"The message that can be drawn is that

the vaccines are going to work against the New York, South African and UK variants,

" Nathan Landau, a virologist at the New York University Grossman School of Medicine, told The New York Times. York, who ran one of the studies.

Experts analyze whether the use of J & J's vaccine against COVID-19 is authorized

April 23, 202100: 39

Demand for the vaccine falls

Despite experts' warning about the efficacy and safety of vaccines licensed in the country, in some places many people are rejecting shipments.

It is paralyzing

.

Some people don't want it, ”Stacey Hileman, a health department nurse in the rural district of Decatur, Kansas, told The Associated Press news agency, where less than a third of the 2,900 residents have even received the first dose.

More than half of adults in the United States have received at least one dose, and the president this week celebrated exceeding his goal of applying 200 million doses in his first 100 days in office.

He also spoke of a new stage in which he hopes to overcome the reluctance of some to receive the vaccine.

Barbara Gennaro, a mother of two in Yazoo City, Mississippi, said everyone in her neighborhood opposes the vaccine.

"All the strong Christians I have relationships with oppose it," he said.

"The greater the trust in the Lord, the less likely they will want the vaccine or consider it necessary," he added.

With information from AP and The New York Times.

Source: telemundo

All news articles on 2021-04-24

You may like

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.